Neopeutics has shown integrity in partnering with its customers at every stage of the drug discovery process
MOUNTAIN VIEW, Calif., March 3, 2015 /PRNewswire/ — Based on its recent analysis of the enhanced drug discovery market, Frost & Sullivan recognizes Neopeutics, Inc. with the 2015 North America Frost & Sullivan Award for Technology Leadership. Neopeutics has demonstrated a remarkable ability to innovate by offering clients a robust, cost-effective, and easily adaptable set of drug discovery instruments. It uniquely focuses on agents that are catalogued as failing compounds in the early stages of the drug discovery process, enabling customers to lower attrition rates and save drug development costs.
Neopeutics recognized with the 2015 North American Enhanced Drug Discovery Technology Leadership Award
Photo – http://photos.prnasia.com/prnh/20150303/8521501311
Photo – http://photos.prnewswire.com/prnh/20150302/178914
Neopeutics’ contract research activities for regulatory agencies and industry players mainly comprise drug-discovery assistance, data analysis and interpretation, advisory and value-add services, and quality assurance (QA). Therefore, its main products are bioinformatics software, drug screening technology packages, and therapeutic compounds derived from natural resources.
One of the main distinguishing factors of Neopeutics is its dedication to introducing natural herbal products, pharmaceuticals, and therapeutics in the global biopharmaceutical market. It is achieving this through a multi-service drug discovery hub for nature-based therapeutics, which offers a distinct, affordable, high-standard QA/quality control (QC) service. Its end-to-end set of bioinformatics tools and expertise greatly assists the development of flexible, customized software tools such as genomics and proteomics platforms for drug screening and discovery.
Neopeutics’ technology platform has been commercialized not only among large pharmaceutical companies, but also small and medium enterprises, aiding the analysis of nature-based herbal products and nutraceuticals. During the screening phase, bioactive ingredients are extracted, separated, analyzed, and then profiled according to their potential therapeutic action.
“Neopeutics’ technology platform speeds up the identification of new therapeutic candidates by elucidating the mechanisms of action and signaling pathways, followed by the chemical agents in several in silico models,” said Frost & Sullivan Industry Analyst Cecilia Van Cauwenberghe. “Such early screening of compounds helps to guarantee a good safety profile for the agents under study.”
The company’s highly efficient and accurate technology helps determine the behavior of a wide range of compounds with their targets and allows the provision of QA services as a natural extension of its services. Since smaller manufacturers do not possess the facilities, financial resources, or expertise to perform QA, they will benefit greatly from Neopeutics’ techno-marketing. Similarly, it aids government regulatory agencies in establishing the mode of action and safety profiles of herbal medication, which is an important step in the regulatory and approval processes.
“Neopeutics is currently using a first-generation version of its proprietary software package of bioinformatics software tools for the drug screening market, while simultaneously working on launching its second-generation package,” noted Van Cauwenberghe. “It also leverages its bioinformatics capabilities to add value to other in-house, tailor-made solutions and enrich key components. Most of these services are coupled with assessment programs, as well as data analysis and interpretation services.”
Furthermore, the company has strategic advantages in terms of both geography and business development. Its two main locations in the United States and Malaysia are ideal to help it enhance business development activities with the major regional players.
Overall, for its strong integrative strategy and dedication to delivering novel nature-based pharmaceuticals, Neopeutics has been presented with the 2015 Frost & Sullivan Technology Leadership Award.
Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impacts both the functionality and the customer value of the new products and applications. The award lauds the high R&D spend toward innovation, its relevance to the industry and the positive impact on brand perception.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
About Neopeutics, Inc.
Neopeutics is an early stage drug discovery contract research partner that offers our partners and clients a robust and cost effective set of pre-clinical drug discovery tools. Our proprietary ChemoMAP® technology package is perfectly suited for “failing” compounds in the early stages of drug discovery, thereby helping to achieve notable savings in drug development costs. In addition, our discovery platform can also help our clients enhance the accuracy and speed of their “hit” identification process as well as elucidate the mode of action and confirm the efficacy and safety of their in-development and on-the-market products, thereby helping to improve drug safety and build consumer confidence.
As systems biology opens up limitless possibilities in drug discovery, we invite you to explore the horizon of drug discovery with us.
For more information, please visit www.neopeutics.com, or contact us at firstname.lastname@example.org.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on “the next big thing”
Register: Gain access to visionary innovation
P: +1.210. 247.3870